Karma may have caught up with Martin Shkreli, but America’s drug pricing problem isn’t about one man
December 18, 2015Manufacturing and Production, Sales and Marketing Daraprim, Martin Shkreli, Turing Pharmaceuticals
As so often occurs in situations of this kind, Twitter reacted with a significant amount of glee and schadenfreude to …
Servier UK appoints new chief executive
December 18, 2015Manufacturing and Production, Research and Development, Sales and Marketing Arnaud Lallouette, Mike Sumpter, Servier
Dr Arnaud Lallouette has been appointed chief executive of Servier Laboratories, the UK subsidiary of the French-based pharma firm, after …
Horizon chief exec Walbert to head up US biotech trade body
December 18, 2015Manufacturing and Production, Research and Development, Sales and Marketing Illinois Biotechnology Industry Organisation, Timothy Walbert, iBio, illinois
Timothy Walbert, the chairman, president and chief executive of Horizon Pharma, has been elected as chairman of the board of …
ViiV Healthcare to acquire Bristol-Myers Squibb’s HIV pipeline drugs
December 18, 2015Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, HIV, ViiV, ViiV Healthcare
Specialist HIV company ViiV Healthcare has agreed deals worth up to $1.46 billion to purchase Bristol-Myers Squibb’s late stage HIV …
Astellas investigated for ‘misleading’ PMCPA during ABPI code complaint
December 18, 2015Medical Communications ABPI Code, Astellas, Astellas Pharma Europe, PMCPA, Prescription Medicines Code of Practice Authority
The Prescription Medicines Code of Practice Authority is investigating Astellas for deliberately providing an ‘incomplete and misleading’ response to a …
Prime Medical Group expands senior editorial team
December 17, 2015Medical Communications Prime Medical Group
The Prime Medical Group has announced the appointment of Valerie Moss PhD to the position of editorial & scientific executive …
Alliance Pharma buys Sinclair’s healthcare products business for £132m
December 17, 2015Manufacturing and Production, Sales and Marketing Alliance Pharma, Sinclair IS Pharma, acquisitions, dermatology merger
Alliance has completed a £132 million purchase of Sinclair IS Pharma’s non-aesthetics healthcare business as it moves to strengthen its …
FDA approves Lilly/Boehringer Lantus biosimilar
December 17, 2015Medical Communications, Sales and Marketing Basaglar, Boehringer Ingelheim, Eli Lilly, Lantus, Sanofi, abasaglar, biosimilar, diabetes, insulin, lilly
The FDA has approved Eli Lilly and Boehringer Ingelheim’s long-acting insulin Basaglar (insulin glargine injection – a biosimilar to rival Sanofi’s …
Pharma company accused of ‘bribing’ prescribers slammed by PMCPA
December 17, 2015Medical Communications ABPI Code, Daily Telegraph, PMCPA, Prescription Medicines Code of Practice Authority, Stirling Anglian
Stirling Anglian, the company at the centre of media criticism for arranging meetings at lavish hotels in an attempt to …
Turing chief exec Martin Shkreli arrested
December 17, 2015Medical Communications, Sales and Marketing Daraprim, FBI, Martin Shkreli, Shkreli, turing
Turing chief executive Martin Shkreli has been arrested on a charge of securities fraud relating to a company he founded, …
Clinical trials increasingly funded by pharma industry
December 17, 2015Research and Development JAMA, Journal of the American Medical Association, NIH, National Institutes of Health, clinical trials, clinicaltrials.gov, pharma, research
The number of clinical trials funded by pharma has risen significantly since 2006, while the number funded by the US …
AstraZeneca to buy majority share in Acerta Pharma
December 17, 2015Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, mergers
Following several days of speculation, AstraZeneca has announced that it has agreed a deal to buy Acerta Pharma, a developer …
Valeant hires attorney and crisis management firm to handle bad US PR
December 17, 2015Medical Communications, Sales and Marketing Robert Kelner, Valeant, Vianovo. Covington & Burling
Valeant has retained attorney Robert Kelner, a partner at the law firm Covington & Burling, to help the beleaguered pharma …
US ‘star’ Bradner to head Novartis Institute of Biomedical Research
December 17, 2015Research and Development James Bradner, Jay Bradner, Mark Fishman, Novartis, Novartis Institute for Biomedical Research
Novartis has hired James ‘Jay’ Bradner, from Harvard’s Dana-Farber Cancer Institute, to head its Institutes for Biomedical Research from 1 …
Gilead’s Sovaldi wins Drug Discovery of the Year Award
December 16, 2015Research and Development British Pharmacological Society, Gilead, Gilead Sciences, hepatitis C, sofosbuvir, sovaldi
Gilead Science’s hepatitis C treatment Sovaldi has been awarded the British Pharmacological Society’s prestigious Drug Discovery of the Year 2016. …
Archbishop of York to become patron of national charity tackling superbugs
December 16, 2015antibiotic resistance
Antibiotic Research UK (ANTRUK), a charity founded in 2014 to save modern medicine from the onslaught of superbugs, has announced …
MSD UK appoints Jessica Fine as executive director of external affairs
December 16, 2015Medical Communications Jessica Fine, MSD
MSD has appointed former Lexington Health boss Jessica Fine to lead its external affairs team in the UK from April …
New final NICE guidance on AbbVie, BMS, Pfizer and Roche drugs
December 16, 2015Sales and Marketing BioMarin Pharma, Enbrel, Humira, Ikervis, MPS IVa, NICE, NICE guidance, Orencia, RoActemra, Santen, apremilast, ciclosporin, dry eye syndrome, juvenile idiopathic arthritis, otezla, psoriatic arthritis, vimizin
NICE has published final guidance on several drugs, approving therapies for juvenile idiopathic arthritis, dry eye disease and Morquio A …
Avacta appoints Tony Gardiner as chief financial officer
December 16, 2015Medical Communications Avacta Group
Avacta Group, the developer of Affimer biotherapeutics and research reagents, has appointed Tony Gardiner as group chief financial officer. Gardiner …
Analysts say pharma R&D returns challenged by drag of high costs
December 16, 2015Research and Development, Sales and Marketing R&D, drug development, research and development, return of investment, sales, sales forecasts
The projected rate of return on pharma industry research and development has more than halved since 2010, from 10.1% to …
Latest content
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
